纯素功能化结合物作为腺素受体的分子探针
Kenneth A Jacobson1, John W Daly1
1Laboratory of Bioorganic Chemistry, National Inst. of Diabetes, Digestive, and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892.
概括
研究人员探索了结构变化如何影响生物活动,使用功能化同源. 这一策略产生了用于药理学应用的腺受体和潜在药物合物的探针.
科学领域:
- 药用化学 医学化学
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 了解结构-活性关系对于药物设计至关重要.
- 氨酸受体在各种生理过程中起着关键作用.
- 开发特定的探头有助于研究受体功能.
研究的目的:
- 为了研究远端结构修改对生物活动的影响.
- 合成和表征用于腺受体的功能化同源探针.
- 设计新型药物合物,包括前期药物和脂质,作为潜在的治疗剂.
主要方法:
- 使用"功能化同源"策略与反应性链.
- 合成的纯氨酸氨基原体 (XAC,ADAC,APEC) 用于腺受体研究.
- 开发了用于光亲和度标记,化学亲和度标记,光谱和亲和度色谱的探针.
主要成果:
- 成功获得了腺A1受体 (XAC,ADAC) 和A2受体 (APEC) 的探针.
- 在各种生化和生物物理技术中证明了这些同源的实用性.
- 具有潜在药理价值的设计和拟议药物合物.
结论:
- 功能化共生体是研究结构-活动关系的有效工具.
- 开发的探针为腺受体研究提供了有价值的试剂.
- 这种方法为开发新的药理学药剂提供了一个有前途的途径.
相关概念视频
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.5K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.5K
Adrenergic Agonists: Direct-Acting Agents
1.4K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.4K
Adrenergic Agonists: Indirect-Acting Agents
1.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.5K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
805
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
805
Adrenergic Receptors: ɑ Subtype
1.4K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.4K
Drug-Receptor Interaction: Agonist
2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K


